Contemporary drug-eluting stents and companion polymers: durable is not synonymous with harm.
作者信息
Cassese Salvatore, Kufner Sebastian, Kastrati Adnan
机构信息
German Heart Center Munich, Technical University Munich, (SC, SK, AK), Munich, Germany.
German Heart Center Munich, Technical University Munich, (SC, SK, AK), Munich, Germany;; German Centre for Cardiovascular Research, Partner Site Munich Heart Alliance (AK), Munich, Germany.
出版信息
J Thorac Dis. 2016 Oct;8(10):E1413-E1415. doi: 10.21037/jtd.2016.10.70.
Abstract
摘要
相似文献
1
Contemporary drug-eluting stents and companion polymers: durable is not synonymous with harm.
J Thorac Dis. 2016 Oct;8(10):E1413-E1415. doi: 10.21037/jtd.2016.10.70.
2
Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial.
Lancet. 2019 Oct 5;394(10205):1243-1253. doi: 10.1016/S0140-6736(19)31877-X. Epub 2019 Sep 2.
3
Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial.
Lancet. 2011 Dec 3;378(9807):1940-8. doi: 10.1016/S0140-6736(11)61672-3. Epub 2011 Nov 8.
4
Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial.
JACC Cardiovasc Interv. 2013 Aug;6(8):777-89. doi: 10.1016/j.jcin.2013.04.011.
5
Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial.
Lancet. 2017 Oct 21;390(10105):1843-1852. doi: 10.1016/S0140-6736(17)32249-3. Epub 2017 Aug 26.
6
Biodegradable-Polymer Biolimus-Eluting Stents versus Durable-Polymer Everolimus-Eluting Stents at One-Year Follow-Up: A Registry-Based Cohort Study.
Tex Heart Inst J. 2016 Apr 1;43(2):126-30. doi: 10.14503/THIJ-14-4997. eCollection 2016 Apr.
7
Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial.
Lancet. 2014 Dec 13;384(9960):2111-22. doi: 10.1016/S0140-6736(14)61038-2. Epub 2014 Sep 1.
8
Ultrathin-strut, biodegradable-polymer, sirolimus-eluting stents versus thin-strut, durable-polymer, everolimus-eluting stents for percutaneous coronary revascularisation: 5-year outcomes of the BIOSCIENCE randomised trial.
Lancet. 2018 Sep 1;392(10149):737-746. doi: 10.1016/S0140-6736(18)31715-X. Epub 2018 Aug 28.
9
Safety and efficacy profile of bioresorbable-polylactide-polymer-biolimus-A9-eluting stents versus durable-polymer-everolimus- and zotarolimus-eluting stents in patients with acute coronary syndrome.
Catheter Cardiovasc Interv. 2016 Nov 15;88(6):E173-E182. doi: 10.1002/ccd.26617. Epub 2016 Jul 5.
10
Acute Thrombogenicity of a Durable Polymer Everolimus-Eluting Stent Relative to Contemporary Drug-Eluting Stents With Biodegradable Polymer Coatings Assessed Ex Vivo in a Swine Shunt Model.
JACC Cardiovasc Interv. 2015 Aug 17;8(9):1248-1260. doi: 10.1016/j.jcin.2015.03.029.
本文引用的文献
1
Randomized Comparison of a Biodegradable Polymer Ultrathin Strut Sirolimus-Eluting Stent With a Biodegradable Polymer Biolimus-Eluting Stent in Patients Treated With Percutaneous Coronary Intervention: The SORT OUT VII Trial.
Circ Cardiovasc Interv. 2016 Jul;9(7). doi: 10.1161/CIRCINTERVENTIONS.115.003610.
2
Bioresorbable Vascular Scaffolds for Coronary Revascularization.
Circulation. 2016 Jul 12;134(2):168-82. doi: 10.1161/CIRCULATIONAHA.116.021539.
3
Stent Thrombosis With Drug-Eluting Stents and Bioresorbable Scaffolds: Evidence From a Network Meta-Analysis of 147 Trials.
JACC Cardiovasc Interv. 2016 Jun 27;9(12):1203-1212. doi: 10.1016/j.jcin.2016.03.038. Epub 2016 Jun 1.
4
Bioresorbable Vascular Scaffold Technology Benefits From Healthy Skepticism.
J Am Coll Cardiol. 2016 Mar 1;67(8):932-935. doi: 10.1016/j.jacc.2015.12.020.
5
Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials.
Lancet. 2016 Feb 6;387(10018):537-544. doi: 10.1016/S0140-6736(15)00979-4. Epub 2015 Nov 17.
6
Stent thrombosis and restenosis: what have we learned and where are we going? The Andreas Grüntzig Lecture ESC 2014.
Eur Heart J. 2015 Dec 14;36(47):3320-31. doi: 10.1093/eurheartj/ehv511. Epub 2015 Sep 28.
7
Coronary Stents: The Impact of Technological Advances on Clinical Outcomes.
Ann Biomed Eng. 2016 Feb;44(2):488-96. doi: 10.1007/s10439-015-1399-z. Epub 2015 Aug 12.
8
Clinical outcomes of patients treated with Nobori biolimus-eluting stent: Meta-analysis of randomized trials.
Int J Cardiol. 2014 Aug 20;175(3):484-91. doi: 10.1016/j.ijcard.2014.06.014. Epub 2014 Jun 28.
9
Biodegradable-polymer drug-eluting stents vs. bare metal stents vs. durable-polymer drug-eluting stents: a systematic review and Bayesian approach network meta-analysis.
Eur Heart J. 2014 May;35(17):1147-58. doi: 10.1093/eurheartj/eht570. Epub 2014 Jan 23.
10
Drug-eluting coronary-artery stents.
N Engl J Med. 2013 Jan 17;368(3):254-65. doi: 10.1056/NEJMra1210816.
Zotero 插件